Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DarioHealth Corp DRIO

DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.


NDAQ:DRIO - Post by User

Post by drbob512on Aug 12, 2020 9:55pm
199 Views
Post# 31401269

Re: DRIO ER & Conf Call:

Re: DRIO ER & Conf Call:As expected, qtr finamcial results were not exciting but just good enough (along with co. making progress) for analysts to congratulate Dario & be rather enthusiastic towards Dario, unlike PING's analysts wbo were subdued. DRIO has big hopes & plans; has won vs. LVGO on a couple head to head competitions. Has gone from only $25M mkt cap to $50M in past few wks due to capital raise of $28.6M, wbich gave investors a reason ti buy it. Why would institutions or accredited investors invest in DRIO when it has such low revenues? The institutions had already owned shares but they double dipped. Because they know these moneys wjll help catapult DRIO into a bina fide player in this space & they like the diabetes platform that Dario has, apparently. Could see an acquisition in the next couple months, imo. Still very risky but if they execute, much higher prices ahead. Jmho dyodd glta.
<< Previous
Bullboard Posts
Next >>